Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (111)

View All

Latest Posts

About This Stock More About This Stock
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Article By: TalkMarkets Newswire
Tuesday, March 1, 2022 8:22 AM EDT
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform.
In this article: SNY, DRIO Also: JNJ, PFE, BNTX
Read
Sanofi SA: An Expected Move Towards The $52.90
Article By: AAATrade
Friday, February 4, 2022 6:55 AM EDT
Today we can expect a move towards the $52.90 resistance, possibly further into the $54 price range, anticipating positive news. 
In this article: SNY
Read
Sanofi Acquires Translate Bio For $38 Per Share In Cash Or $3.2B
Article By: The Fly
Tuesday, August 3, 2021 6:03 AM EDT
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis.
In this article: SNY, TBIO
Read
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Article By: Benzinga
Thursday, May 27, 2021 9:00 AM EDT
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021.
In this article: SNY, GSK
Read
70 Firms Going Ex-Dividend Next Week, Including Walmart, BP And Pfizer
Article By: Timothy J. McIntosh
Saturday, May 1, 2021 8:28 PM EDT
There are several well known large cap stocks going ex-dividend next week. Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
In this article: AEP, BP, IBM, PFE, SNY, WFC, WMT, INTC, O
Read
All Posts

Latest Tweets for $SNY

No tweets yet!

PARTNER HEADLINES

$SNY

Comments Status Updates
There Is Beta In Protalix Stock Due To PRX-102
Paul McGee • 8/28/2020 2:44:13 AM

Isn't that made by Sanofi $SNY?

Protalix BioTherapeutics Pipeline Progress
Harry Goldstein • 8/10/2020 6:01:37 AM

#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY

Protalix BioTherapeutics Pipeline Progress
Old Time Investor • 8/3/2020 2:23:12 PM

My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.

1 to 3 of 3 comments